Abbvie Inc NYSE:ABBV Price, Chart, News & Insight

AbbVie (NYSE: ABBV) gained 1.2% after receiving supportive analyst commentary, as Canaccord Genuity raised its price target to $273 from $265 and Cantor Fitzgerald reiterated its Overweight rating.

The positive analyst actions reflect continued confidence in AbbVie's growth outlook as the company strengthens its portfolio beyond Humira. Investors remain focused on the strong performance of newer immunology drugs Skyrizi and Rinvoq, which have become key drivers of revenue growth and market share gains.

Sentiment was also supported by AbbVie's recently announced acquisition of Apogee Therapeutics, a deal that expands the company's immunology pipeline and reinforces its long-term growth strategy. Analysts view the transaction as a move that could further strengthen AbbVie's leadership position in inflammatory diseases.

The stock's advance suggests investors remain optimistic about the company's ability to generate consistent earnings growth, supported by a diversified pharmaceutical portfolio, strong cash flow generation, and continued business development activity.

With multiple analysts maintaining bullish ratings and raising valuation targets, AbbVie continues to be viewed as one of the leading large-cap pharmaceutical companies positioned for sustainable growth in the years ahead.

💬 🔗

European Investor 06-23-26

AbbVie Rallies After $10.9 Billion Apogee Acquisition and New Wells Fargo Price Target

AbbVie (NYSE: ABBV) rose 4.6% after announcing a $10.9 billion acquisition of Apogee Therapeutics and receiving a new $260 price target from Wells Fargo, reinforcing investor confidence in the company's long-term growth strategy.

Under the agreement, AbbVie will acquire Apogee for $135.11 per share in cash, adding a promising pipeline of immunology and respiratory disease treatments to its portfolio. The deal is centered around zumilokibart (APG777), a late-stage treatment for atopic dermatitis, as well as additional programs targeting asthma and other inflammatory diseases.

Management believes the acquisition will strengthen AbbVie's leadership in immunology, one of its most important therapeutic areas, while creating a new growth platform beyond its existing blockbuster products. The company highlighted the potential for multiple future blockbuster therapies and expects the transaction to become accretive to earnings beginning in 2032.

The positive market reaction suggests investors view the acquisition as a strategic move to expand AbbVie's pipeline and support long-term revenue growth. Combined with Wells Fargo's newly established $260 price target, the announcement helped drive shares sharply higher as investors welcomed the company's continued investment in high-growth areas of biotechnology.

💬 🔗

Global Finance News 06-22-26

AbbVie Beats Q1 Expectations, Raises Full-Year Outlook as Skyrizi and Rinvoq Power Growth

AbbVie (NYSE: ABBV) reported strong first-quarter 2026 results, exceeding analyst expectations and prompting the pharmaceutical giant to raise its full-year earnings guidance.

The company posted net revenues of $15.0 billion for the quarter, representing a 12.4% increase on a reported basis. Adjusted diluted EPS came in at $2.65, a 7.7% year-over-year improvement and ahead of the consensus estimate of $2.59. On a GAAP basis, diluted EPS fell to $0.39 — a decline of 45.8% — largely due to a $0.41-per-share charge tied to acquired in-process research and development (IPR&D) and milestone expenses.

Immunology Leads the Way
AbbVie's immunology franchise remained the engine of growth, generating $7.29 billion in global net revenues, up 16.4% year-over-year. Skyrizi pulled in $4.48 billion and Rinvoq contributed $2.12 billion — both continuing their rapid ascent as replacements for Humira, which brought in a comparatively modest $688 million as biosimilar competition continues to erode its dominance.

Neuroscience Surges
The neuroscience portfolio was another standout, with revenues climbing 26.0% to $2.88 billion. Botox Therapeutic crossed the $1 billion mark at $1.009 billion, while Vraylar contributed $905 million and migraine treatments Ubrelvy and Qulipta combined for $635 million.

Oncology Under Pressure
The oncology segment was a relative weak spot, slipping 0.2% to $1.63 billion. Imbruvica, facing intensifying competition and government drug-pricing negotiations, brought in $556 million, while Venclexta led the portfolio at $770 million.

Guidance Raised
On the strength of the quarter, AbbVie lifted its 2026 adjusted diluted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16. CEO Robert A. Michael called it "an excellent start to 2026," citing strong performance from key growth drivers and a pipeline advancing across all stages of development.

Stock Snapshot
ABBV shares have traded around $200 today, hovering near $204–$205 following the earnings release. The stock is down roughly 13% year-to-date, though today's strong results may offer a near-term catalyst. Its 52-week high stands at $244.81, about 20% above current levels. (Robinhood)

💬 🔗

WS Investor 04-29-26

AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026

💬 🔗

European Investor 03-31-26

Dividend Growth Stocks: Abbvie Inc. (ABBV) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬 🔗

European Investor 03-07-26

AbbVie reported solid fourth-quarter and full-year 2025 results, delivering full-year net revenues of $61.16 billion, up 8.6% year over year, despite a significant drag from acquired IPR&D and milestone expenses. On a GAAP basis, full-year diluted EPS declined 1.3% to $2.36, while adjusted diluted EPS decreased 1.2% to $10.00, reflecting an unfavorable $2.76 per-share impact from 2025 acquired IPR&D and milestones.

Growth was led by the immunology and neuroscience portfolios, which more than offset continued Humira erosion. Full-year immunology revenues rose 14.0% to $30.41 billion, driven by strong performance from Skyrizi ($17.56 billion) and Rinvoq ($8.30 billion). Neuroscience revenues increased 19.6% to $10.77 billion, supported by Vraylar, Botox Therapeutic, and migraine brands Ubrelvy and Qulipta. Oncology revenues grew modestly to $6.66 billion, while aesthetics revenues declined 6.1% to $4.86 billion.

In the fourth quarter, AbbVie posted net revenues of $16.62 billion, up 10.0% year over year. Adjusted diluted EPS was $2.71, compared with GAAP diluted EPS of $1.02, reflecting a $0.71 per-share headwind from acquired IPR&D and milestone expenses. For 2026, the company issued adjusted diluted EPS guidance of $14.37 to $14.57, excluding any unfavorable impact from acquired IPR&D and milestones, signaling confidence in continued growth momentum.

Source: AbbVie, PRNewswire, February 4, 2026.

💬 🔗

WS Investor 02-06-26

AbbVie Inc. updated its 2025 guidance to reflect acquired IPR&D and milestone expenses recorded in the fourth quarter.

For Q4 2025, AbbVie reported $1.27 billion in acquired IPR&D and milestone expenses, reducing adjusted diluted EPS by $0.71. As a result, adjusted diluted EPS guidance for the quarter was lowered to a range of $2.61–$2.65.

For the full year 2025, the same $1.27 billion expense reduced adjusted diluted EPS by $0.71, bringing full-year adjusted diluted EPS guidance to $9.90–$9.94, compared with the prior range of $10.61–$10.65.

💬 🔗

The Investor 01-08-26

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens.

💬 🔗

Global Finance News 01-07-26

AbbVie Reports Strong Q3 2025 Results with 9% Revenue Growth, Lifts Full-Year Outlook

AbbVie (NYSE: ABBV) posted third-quarter 2025 revenues of $15.78 billion, up 9.1% year-over-year (8.4% operationally), driven by continued strength in immunology and neuroscience portfolios. GAAP EPS was $0.10, while adjusted EPS stood at $1.86, down 38%, reflecting a $1.50 per-share impact from acquired IPR&D and milestones expense.

The immunology portfolio led performance with $7.89 billion in revenue (+11.9%), fueled by Skyrizi ($4.71 billion, +46.8%) and Rinvoq ($2.18 billion, +35.3%), offsetting Humira’s expected decline (-55%).

Neuroscience sales rose 20.2% to $2.84 billion, supported by Vraylar ($934 million), Botox Therapeutic ($985 million), and migraine treatments Ubrelvy and Qulipta (combined $642 million).

The oncology segment slipped 0.3% to $1.68 billion, while aesthetics declined 3.7% to $1.19 billion, as Botox Cosmetic and Juvederm faced softer demand.

AbbVie’s adjusted operating margin was 30.9%, with a 24.5% adjusted tax rate, and the company reaffirmed its long-term EPS growth target of 5–7% through 2029.

Citing strong business momentum, AbbVie raised its full-year adjusted EPS guidance to $10.61–$10.65 (from $10.38–$10.58) and announced a 5.5% dividend increase for 2026, payable in February. CEO Robert A. Michael highlighted progress in innovation and pipeline development as key drivers of long-term growth.

💬 🔗

The Investor 10-31-25

AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.

💬 🔗

WS Investor 10-02-25

NYSE:ABBVFollow

Dividend Growth Stocks: Abbvie Inc. (ABBV) Dividend Stock Analysis

NYSE:ABBV